Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 218

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 218
---
 | For the Years Ended 
 December 31,        
 2024                |    (Pro forma, 
    Predecessor 
 and Successor) |   |     |   |          2023 
 (Predecessor) |   |     |   | Difference |   |
|:-----------------------------------------------------|:----|:--------------------|---------------:|:--|:----|:--|--------------:|:--|:----|:--|-----------:|:--|
| Net cash used in operating activities                |     | $                   |    (12,915,969 | ) |     | $ |    (5,789,987 | ) |     | $ | (7,125,982 | ) |
| Net cash provided by financing activities:           |     |                     |     13,727,634 |   |     |   |       571,678 |   |     |   | 13,155,956 |   |
| Net increase (decrease) in cash and cash equivalents |     | $                   |        811,665 |   |     | $ |    (5,218,309 | ) |     | $ |  6,029,974 |   |

Net cash used in operating activities Net cash used in operating activities for the three months ended March 31, 2025 primarily reflected a net loss of $5.1 million, adjusted for the reconciliation of non-cash items such as depreciation expense of $0.1 million, stock-based compensation of $0.3 million, inducement expense of $0.2 million, and amortization of right-of-use asset of $0.2 million, and changes in operating asset and liabilities primarily consisting of an increase in prepaid expenses and other current assets of $0.3 million, an increase in accounts payable of $0.7 million, a decrease in accrued liabilities of $0.3 million, and a decrease in operating lease liabilities of $0.2 million. Net cash used in operating activities for the three months ended March 31, 2024 primarily reflected a net loss of $2.3 million, adjusted for the reconciliation of non-cash items such as a gain of settlement of liabilities with vendors of $0.1 million, depreciation expense of $0.1 million, stock-based compensation of $0.1 million, amortization of right-of-use asset of $0.2 million and a gain on revaluation of earnout liability and the preferred stock